Aims and Scope
BMC Cancer is a peer-reviewed open access medical journal that publishes original research on cancer and oncology. It was established in 2001 and is published by BioMed Central.
Key Metrics
6.7
CiteScore
CiteScore
CiteScore measures average citations received per document published in the serial.
0.05 - 0.1
Eigenfactor
Eigenfactor
Eigenfactor Score measures the number of times articles from the journal published in the past five years have been cited. This does not include self citations.
< 5
Impact Factor
Impact Factor
Impact factor of a journal is calculated by dividing the number of current year citations to the source items published in that journal during the previous two years.
0.88
5-Year SI
5-year SI
- 0.87 2-year SI
- 0.87 Lifetime SI
Scite Index
Scite Index
scite Index is the ratio of citations supporting research which is published in the journal to sum of citations either supporting or contrasting the research published in the journal for the same time period. Minimum 100 supporting citations required.
Q2
Genetics
SJR
- Q2 Genetics
- Q2 Oncology
- Q2 Cancer Research
SJR
SJR
SCImago Journal Rank measures weighted citations received by the serial. Citation weighting depends on subject field and prestige (SJR) of the citing serial.
1.31
SNIP
SNIP
Source Normalized Impact per Paper measures actual citations received relative to citations expected for the serial’s subject field.
6 Mo
Time to Publish
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
Topics Covered
- Cancer
- Assay
- Overall survival
- Lung cancer
- Gene expression
- Lymph node
- Chemotherapy
- Positron emission tomography
- Neuroendocrine tumors
- Breast cancer
- Confidence interval
- Toxicity
- Hepatocellular carcinoma
- Radiation
- Machine learning
- Tumor microenvironment
- Chemoradiotherapy
- Lung
- Cell growth
- Cell cycle
Journal Specifications
| Overview | |
| Publisher | BMC |
| Language | English |
| Frequency | Continuous publication |
| Article Processing Charges | GBP 2190 | USD 2990 | EUR 2590 |
| Publication Time | 19 |
| Editorial Review Process | Open peer review |
| General Details | |
| Language | English |
| Frequency | Continuous publication |
| Publication Start Year | 2001 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Plagiarism | Visit website |
| Waiver Policy | Visit website |
| Publication Time | 19 |
| Article Processing Charges | GBP 2190 | USD 2990 | EUR 2590 |
| Editorial Review Detail | |
| Editorial Team | Visit website |
| Review Process | Open peer review |
| Review Url | Visit website |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC0 |
| OA statement | Visit website |
Planning to publish in BMC Cancer ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Looking for the right journals to submit your mansucript?
Upload your manuscript and get a submission readiness score and other journal recommendations.
Check my PaperRecently Published Papers
-
Full paper
Humanized anti-DEspR IgG4 S228P antibody increases overall survival in a pancreatic cancer stem cell-xenograft peritoneal carcinomatosis rat nu/nu model
- 14 Apr 21
- BMC Cancer
-
Full paper
Factors determining ultra-short-term survival and the commencement of active treatment in high-grade serous ovarian cancer: a case comparison study.
- 8 Apr 21
- BMC Cancer
-
Full paper
False negative rate at 18 F-FDG PET/CT in para-aortic lymphnode involvement in patients with locally advanced cervical cancer: impact of PET technology.
- 6 Feb 21
- BMC Cancer
-
Full paper
Tumor vasculature-targeted 10 B delivery by an Annexin A1-binding peptide boosts effects of boron neutron capture therapy
- 15 Jan 21
- BMC Cancer
-
Full paper
Network meta-analysis of targetedtherapies for diffuse large B cell lymphoma.
- 11 Dec 20
- BMC Cancer
-
Full paper
O 6 -methylguanine DNA methyltransferase and glucose transporter 2 in foregut and hindgut gastrointestinal neuroendocrine neoplasms
- 7 Dec 20
- BMC Cancer
Scite analysis
Powered by scite_
16.4k articles received 371.4k citations see all
- 20,516 Supporting
- 341,015 Mentioning
- 3,026 Contrasting
Editorial notices
- 50 Retractions
- 0 Withdrawals
- 183 Corrections
- 170 Errata
- 1 Expression of Concern
Time To Publish
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
Time to Publish
Based on turnaround time from submission to publication for papers (articles & reviews) published in 2022 and for journals with a sample of more than 10 papers.
% of papers by time taken from submission to publication
0 to 3 months
12%
4 to 6 months
41%
7 to 9 months
27%
Above 9 months
20%
Did you find this useful?
Thank you for your feedback.
FAQs
How long has BMC Cancer been actively publishing?
BMC Cancer has been in operation since 2001 till date.
What is the publishing frequency of BMC Cancer ?
BMC Cancer published with a Continuous publication frequency.
How many articles did BMC Cancer publish last years ?
In 2023, BMC Cancer published articles.
What is the eISSN & pISSN for BMC Cancer ?
For BMC Cancer,eISSN is 1471-2407 and pISSN is1471-2407.
What is Citescore for BMC Cancer ?
Citescore for BMC Cancer is 6.7.
What is SNIP score for BMC Cancer ?
SNIP score for BMC Cancer is 1.31.
What is the SJR for BMC Cancer ?
SJR for BMC Cancer is Q2.
Who is the publisher of BMC Cancer ?
BMC is the publisher of BMC Cancer.